Release Notes:
Data Element
Version 2018A
| Data Element Name: |
Reason for No Aldosterone Receptor Antagonist Prescribed for LVSD in the Outpatient Setting |
|---|
| Collected For: |
ACHFOP-03 |
|---|
| Definition: | Reasons for not prescribing aldosterone receptor antagonist for LVSD in the outpatient setting.
The main action of aldosterone is to increase sodium re-absorption by the kidneys. At the same time it increases the excretion of hydrogen and potassium ions. Aldosterone receptor antagonists block the effects of aldosterone, therefore decrease sodium re-absorption and water retention by the kidneys and consequently lead to a decrease in blood pressure.
Other reasons include hyperkalemia or renal dysfunction or dialysis.
|
|---|
| Suggested Data Collection Question: | Is there documentation of a reason for not prescribing aldosterone receptor antagonist for LVSD in the outpatient setting or a history of hyperkalemia or renal dysfunction or dialysis? |
|---|
| Format: |
| Length: | 1 |
|---|
| Type: | Alphanumeric |
|---|
| Occurs: | 1 |
|---|
|
|---|
| Allowable Values: |
Y (Yes) There is documentation of a reason for not prescribing aldosterone receptor antagonist for LVSD in the outpatient setting.
N (No) There is no documentation of a reason for not prescribing aldosterone receptor antagonist for LVSD in the outpatient setting or unable to determine from medical record documentation.
|
|---|
| Notes for Abstraction: |
- All medication documentation available in the chart should be reviewed and taken into account by the abstractor.
- If the patient is currently on an aldosterone receptor antagonist, answer “Yes”.
|
|---|
| Suggested Data Sources: |
- Outpatient medical record
|
|---|
| Additional Notes: |
|
|---|
| Guidelines for Abstraction: |
|---|
| Inclusion |
Exclusion |
- Spironolactone
- Eplerenone
|
None |
|
Reason for No Aldosterone Receptor Antagonist Prescribed for LVSD in the Outpatient Setting
Specifications Manual for Joint Commission National Quality Measures (v2018A)
Discharges 07-01-18 (3Q18) through 12-31-18 (4Q18)
^